Skip to main content

A Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenous Doses of PF-05231023 in Obese Adult Subjects

A Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenous Doses of PF-05231023 in Obese Adult Subjects

Principal Investigator

Sponsor

Pfizer

PF-05231023 is an investigational new drug. “Investigational” means the study drug is being tested and has not yet been approved by the United States Food and Drug Administration . The study drug is being developed for the treatment of Type 2 Diabetes Mellitus.